IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0789701
(2007-04-25)
|
등록번호 |
US-8293965
(2012-10-23)
|
발명자
/ 주소 |
- McMaken, Jack D.
- Gibbins, Bruce L.
|
출원인 / 주소 |
- Kimberly-Clark Worldwide, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
3 인용 특허 :
136 |
초록
▼
The present invention comprises antimicrobial articles for use with a percutaneous device, comprising a matrix which may contact the percutaneous device in a three-dimensional mode and release antimicrobial agents (e.g., silver ions) to the percutaneous device access site. In addition, the antimicro
The present invention comprises antimicrobial articles for use with a percutaneous device, comprising a matrix which may contact the percutaneous device in a three-dimensional mode and release antimicrobial agents (e.g., silver ions) to the percutaneous device access site. In addition, the antimicrobial article of the present invention may donate moisture to a dry dermal site (e.g., a dry wound bed) and/or absorb liquid or exudates of a dermal site. The present invention also comprises methods for treating and/or preventing an infection using the antimicrobial articles of the present invention.
대표청구항
▼
1. An article of manufacture for use with a percutaneous device, comprising, a matrix, wherein a first portion of the matrix is formed as a generally planar member, and wherein the matrix defines a passage and a curve-shaped slit having a first end, a second end, and a middle, wherein the passage ex
1. An article of manufacture for use with a percutaneous device, comprising, a matrix, wherein a first portion of the matrix is formed as a generally planar member, and wherein the matrix defines a passage and a curve-shaped slit having a first end, a second end, and a middle, wherein the passage extends from an edge of the matrix to a portion of the curve-shaped slit between the first and second ends of the curve-shaped slit, wherein the matrix further comprises: an antimicrobial agent; and a second portion of the matrix, defined by the intersection of the passage and the curve-shaped slit, wherein the second portion of the matrix forms a three-dimensional contact with the percutaneous device above the surface of the skin, wherein the first portion of the matrix and the second portion of the matrix are in different planes from each other above the surface of the skin. 2. The article of claim 1, wherein the antimicrobial agent is a silver containing compound. 3. The article of claim 1, wherein the matrix further comprises at least one additional active agent. 4. The article of claim 3, wherein the active agent is an antifungal agent, an antibacterial agent, an anti-viral agent, an antiparasitic agent, an anaesthetic, a mucopolysaccharide, a growth factor, a protein, an angiogenic factor, a wound healing agent or adjuvant, or combinations thereof. 5. The article of claim 4, wherein the protein is collagen, cross-linked collagen, fibronectin, laminin, elastin, cross-linked elastin, antibodies, or combinations or fragments thereof. 6. The article of claim 4, wherein the growth factor is basic fibroblast growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factors 1 and 2, platelet derived growth factor, tumor angiogenesis factor, vascular endothelial growth factor, corticotrophin releasing factor, transforming growth factors, alpha. and .beta., interleukin-8, granulocyte-macrophage colony stimulating factor, interleukins, or interferons. 7. The article of claim 4, wherein the mucopolysaccharide is heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose, agarose, chitin, dextran, carrageenin, linoieic acid, or allantoin. 8. The article of claim 1, wherein the antimicrobial agent is isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tretracycline, erythromycin, ciprofloxacin, doxycycline, ampicillin, amphotericin B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycine, diclazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, Zn-pyrithione, silver salts of chloride, bromide, iodide or periodate. 9. The article of claim 1, wherein the matrix is made from a natural or synthetic hydrophilic polymer. 10. The article of claim 9, wherein the polymer is collagen, animal hide, hyaluronic acid, dextran, alginate, hydrophilic fibers of cross-linked and/or non-cross-linked celluloses, carboxymethy cellulose, hydroxymethyl cellulose, cotton, rayon, fibers made from polyacrylates, fibers of calcium alginates, polyacrylamide, polyvinyls, PVP, PVC, polyacrylate, polybuterate, polyurethane foam, silicone elastomer, rubber, nylon, vinyl, or cross linked dextran. 11. The article of claim 1, wherein the passage extends from the edge of the matrix to the middle of the slit. 12. The article of claim 1, wherein the curve-shaped slit is defined by two ends that are not connected together. 13. The article of claim 1, wherein the matrix is translucent, semi-transparent, or transparent. 14. A method of treating or preventing an infection, comprising, contacting a percutaneous device with a matrix, wherein a first portion of the matrix is formed as a generally planar member, wherein the matrix defines a passage and a curve-shaped slit having a first end, a second end, and a middle, wherein the passage extends from an edge of the matrix to a portion of the curve-shaped slit between the first and second ends of the curve-shaped slit, wherein the matrix further comprises: an antimicrobial agent, wherein contacting the percutaneous device comprises selectively forming a three-dimensional contact with a portion of the percutaneous device, in which a second portion of the matrix, defined by the intersection of the passage and the curve-shaped, forms contact with the percutaneous device above the surface of the skin, wherein the first portion of the matrix and the second portion of the matrix are in different planes from each other above the surface of the skin. 15. The method of claim 14, wherein the antimicrobial agent is a silver containing compound. 16. The method of claim 14, wherein the matrix further comprising comprises at least one additional active agent in the matrix. 17. The method of claim 16, wherein the active agent is an antifungal agent, an antibacterial agent, an anti-viral agent, an antiparasitic agent, an anaesthetic, a mucopolysaccharide, a growth factor, a protein, an angiogenic factor, a wound healing agent or adjuvant, or combinations thereof. 18. The method of claim 17, wherein the protein is collagen, cross-linked collagen, fibronectin, laminin, elastin, cross-linked elastin, antibodies, or combinations or fragments thereof. 19. The method of claim 17, wherein the growth factor is basic fibroblast growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factors 1 and 2, platelet derived growth factor, tumor angiogenesis factor, vascular endothelial growth factor, corticotrophin releasing factor, transforming growth factors alph. and .beta., interleukin-8, granulocyte-colony stimulating factor, interleukins, or interferons. 20. The method of claim 17, wherein the mucopolysaccharide is heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose, agarose, chitin, dextran, carrageenin, linoleic acid, or allantoin. 21. The method of claim 14, wherein the antimicrobial agent is isoniazid, ethambutol, Pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, ciprofloxacin, doxycycline, ampicillin, amphotericin B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclarzaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, microazole, Zn-pyrithione, silver salts of chloride, bromide, iodide or periodate. 22. The method of claim 14, wherein the matrix is made from a natural or synthetic hydrophilic polymer. 23. The method of claim 22, wherein the polymer is collagen, animal hide, hyaluronic acid, dextran, alginate, hydrophilic fibers of cross-linked and/or non-crosslinked celluloses, carboxymethy cellulose, hydroxymethyl cellulose, cotton, rayon, fibers made from polyacrylates, fibers of calcium alginates, polyacrylamide, polyvinyls, PVP, PVC, polyacrylate, polybuterate, polyurethane foam, silicone elastomer, rubber, nylon, vinyl, or cross linked dextran. 24. The method of claim 14, wherein the passage extends from the edge of the matrix to the middle of the slit. 25. The method of claim 14, wherein the curve-shaped slit is defined by two ends that are not connected together. 26. The method of claim 14, wherein the matrix is translucent, semi-transparent, or transparent.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.